9:00 AM SIGN-IN • 9:30 AM - 11:00 AM
BANDOL 1 (NEW WYNN SPACE)
CE: Wet Age-Related Macular Degeneration: Examining Clinical and Economic Data
Neovascular or wet age-related macular degeneration (AMD) accounts for 10% to 15% of all cases of AMD. Wet AMD is responsible for about 90% of the loss of severe visual acuity due to accumulation of retinal fluid. Improved imaging technologies and home monitoring systems are transforming the management and diagnosis of patients with wet AMD. However, data indicate that wet AMD may still be underdiagnosed in the United States, and treatment delays can considerably contribute to economic burden for patients, caregivers, and the health care system. Approved and emerging treatment options with anti-vascular endothelial growth factor (VEGF) biologics offer individualized regimens for patients with wet AMD. Specialty pharmacists are well positioned to engage with managed care professionals and payers on the value of best practices to reduce the associated treatment burden of this disease. This session will explore extended dosing schedules of anti-VEGF biologics as well as the pharmacist’s role in promoting strategies for early and aggressive treatment to improve outcomes for patients with wet AMD.